-
Je něco špatně v tomto záznamu ?
Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study
V. Kamenský, L. Dostálek, M. Rožánek, A. Tichopád, R. Prymula, I. Šarkanová
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2001-12-01
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2001
Free Medical Journals
od 2001
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Medline Complete (EBSCOhost)
od 2001-01-01
Health & Medicine (ProQuest)
od 2009-01-01
Public Health Database (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
Springer Nature OA/Free Journals
od 2001-12-01
- MeSH
- analýza nákladové efektivity MeSH
- analýza nákladů a výnosů * MeSH
- dospělí MeSH
- infekce papilomavirem * prevence a kontrola ekonomika MeSH
- kvalitativně upravené roky života * MeSH
- lidé MeSH
- Markovovy řetězce * MeSH
- mladiství MeSH
- mladý dospělý MeSH
- očkovací programy ekonomika MeSH
- osobní újma zaviněná nemocí MeSH
- vakcíny proti papilomavirům * ekonomika aplikace a dávkování MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
OBJECTIVES: Human papillomavirus (HPV) infections are highly prevalent sexually transmitted infections, notably associated with various cancers. This study analyses the health and economic impacts of HPV-associated diseases in the Czech Republic and evaluates the cost-effectiveness of a catch-up vaccination program. METHODS: Utilizing a Markov multistate model, the study assesses the lifetime impacts and costs related to HPV infections. Cohorts of ages 15-21 were simulated to assess the impact of catch-up vaccination outside the 11-year-old age group. RESULTS: The total quality-adjusted life years (QALYs) for the female and male cohorts (together 119,362 individuals) were higher in the vaccination scenario compared to the non-vaccination scenario. The increase in QALYs was 122,246 and 200,852 respectively, when considering the actual vaccination rates. Across both cohorts, 329 cancer-related deaths were prevented. In the probabilistic sensitivity analysis for the female population, vaccination was the dominant strategy in 99.3% of iterations. In the male population, vaccination was the dominant strategy in 80.3% of iterations. The implementation of catch-up vaccination for the 15-21 age group significantly increased QALY gains and reduced life-years-lost (LYLs). In the female cohort, all analysed rates of catch-up vaccination were the dominant strategy, while in the male cohort, the incremental cost-effectiveness ratios (ICERs) remained consistently below 42,000 CZK/QALY. CONCLUSIONS: The catch-up vaccination program for 15-21-year-olds is cost-effective and can prevent a significant number of HPV-related cancers in both men and women.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009935
- 003
- CZ-PrNML
- 005
- 20250429134954.0
- 007
- ta
- 008
- 250415s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12889-025-21599-6 $2 doi
- 035 __
- $a (PubMed)39910575
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Kamenský, Vojtech $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, Prague, 272 01, Czech Republic
- 245 10
- $a Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic: a model-based study / $c V. Kamenský, L. Dostálek, M. Rožánek, A. Tichopád, R. Prymula, I. Šarkanová
- 520 9_
- $a OBJECTIVES: Human papillomavirus (HPV) infections are highly prevalent sexually transmitted infections, notably associated with various cancers. This study analyses the health and economic impacts of HPV-associated diseases in the Czech Republic and evaluates the cost-effectiveness of a catch-up vaccination program. METHODS: Utilizing a Markov multistate model, the study assesses the lifetime impacts and costs related to HPV infections. Cohorts of ages 15-21 were simulated to assess the impact of catch-up vaccination outside the 11-year-old age group. RESULTS: The total quality-adjusted life years (QALYs) for the female and male cohorts (together 119,362 individuals) were higher in the vaccination scenario compared to the non-vaccination scenario. The increase in QALYs was 122,246 and 200,852 respectively, when considering the actual vaccination rates. Across both cohorts, 329 cancer-related deaths were prevented. In the probabilistic sensitivity analysis for the female population, vaccination was the dominant strategy in 99.3% of iterations. In the male population, vaccination was the dominant strategy in 80.3% of iterations. The implementation of catch-up vaccination for the 15-21 age group significantly increased QALY gains and reduced life-years-lost (LYLs). In the female cohort, all analysed rates of catch-up vaccination were the dominant strategy, while in the male cohort, the incremental cost-effectiveness ratios (ICERs) remained consistently below 42,000 CZK/QALY. CONCLUSIONS: The catch-up vaccination program for 15-21-year-olds is cost-effective and can prevent a significant number of HPV-related cancers in both men and women.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a analýza nákladů a výnosů $7 D003362
- 650 12
- $a infekce papilomavirem $x prevence a kontrola $x ekonomika $7 D030361
- 650 _2
- $a mladiství $7 D000293
- 650 12
- $a vakcíny proti papilomavirům $x ekonomika $x aplikace a dávkování $7 D053918
- 650 12
- $a Markovovy řetězce $7 D008390
- 650 _2
- $a mladý dospělý $7 D055815
- 650 12
- $a kvalitativně upravené roky života $7 D019057
- 650 _2
- $a osobní újma zaviněná nemocí $7 D017281
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a očkovací programy $x ekonomika $7 D017589
- 650 _2
- $a analýza nákladové efektivity $7 D000094703
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Dostálek, Lukáš $u Department of Gynaecology and Obstetrics, 1st Medical Faculty of Charles University, General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Rožánek, Martin $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, Prague, 272 01, Czech Republic
- 700 1_
- $a Tichopád, Aleš $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, Prague, 272 01, Czech Republic
- 700 1_
- $a Prymula, Roman $u Research Institute for Biomedical Science (RIBS), Hradec Kralove, Czech Republic $u Institute of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
- 700 1_
- $a Šarkanová, Ivana $u Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, nám. Sítná 3105, Prague, 272 01, Czech Republic. ivana.sarkanova@fbmi.cvut.cz
- 773 0_
- $w MED00008205 $t BMC public health $x 1471-2458 $g Roč. 25, č. 1 (2025), s. 481
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39910575 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134949 $b ABA008
- 999 __
- $a ok $b bmc $g 2311359 $s 1247016
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 25 $c 1 $d 481 $e 20250205 $i 1471-2458 $m BMC public health $n BMC Public Health $x MED00008205
- LZP __
- $a Pubmed-20250415
